一个加速癌症治疗优化的联合临床平台。
A co-clinical platform to accelerate cancer treatment optimization.
作者信息
Lunardi Andrea, Pandolfi Pier Paolo
机构信息
Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
出版信息
Trends Mol Med. 2015 Jan;21(1):1-5. doi: 10.1016/j.molmed.2014.10.008. Epub 2014 Nov 17.
Sophistication in DNA and RNA sequencing technology is unraveling the tremendous genetic and molecular complexity of human cancer. However, the rate at which this knowledge is being translated into patient care is too slow. To this end, we have designed and implemented a new translational platform, 'The Co-Clinical Trial Project', where data obtained in genetically engineered mouse models (GEMMs) of human cancer treated with protocols identical to those of ongoing clinical trials or with therapies already established in patients serve to rapidly: (i) stratify patients in terms of response and resistance on the basis of genetic and molecular criteria; (ii) identify mechanisms responsible for tumor resistance; and (iii) evaluate the effectiveness of drug combinations to overcome such resistance based on mechanistic understanding.
DNA和RNA测序技术的复杂性正在揭示人类癌症巨大的遗传和分子复杂性。然而，这些知识转化为患者护理的速度过于缓慢。为此，我们设计并实施了一个新的转化平台——“联合临床试验项目”，在该项目中，通过基因工程小鼠模型（GEMMs）获得的数据，这些模型采用与正在进行的临床试验相同的方案或患者已确立的疗法进行治疗，从而能够迅速：（i）根据遗传和分子标准对患者的反应和耐药性进行分层；（ii）确定肿瘤耐药的机制；（iii）基于机制理解评估药物组合克服此类耐药性的有效性。
Zotero 插件